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Abstract
Background: Diabetes is a strong risk factor for cardiovascular disease (CVD).The relative role of various lipid
measures in determining CVD risk in diabetic patients is still a subject of debate. We aimed to compare
performance of different lipid measures as predictors of CVD using discrimination and fitting characteristics in
individuals with and without diabetes mellitus from a Middle East Caucasian population.
Methods: The study population consisted of 1021 diabetic (men = 413, women = 608) and 5310 non-diabetic
(men = 2317, women = 2993) subjects, aged ≥ 30 years, free of CVD at baseline. The adjusted hazard ratios (HRs)
for CVD were calculated for a 1 standard deviation (SD) change in total cholesterol (TC), log-transformed
triglyceride (TG), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), non-HDL-
C, TC/HDL-C and log-transformed TG/HDL-C using Cox proportional regression analysis. Incident CVD was
ascertained over a median of 8.6 years of follow-up.
Results: A total of 189 (men = 91, women = 98) and 263(men = 169, women = 94) CVD events occurred, in
diabetic and non-diabetic population, respectively. The risk factor adjusted HRs to predict CVD, except for HDL-C,
TG and TG/HDL-C, were significant for all lipid measures in diabetic males and were 1.39, 1.45, 1.36 and 1.16 for TC,
LDL-C, non- HDL-C and TC/HDL-C respectively. In diabetic women, using multivariate analysis, only TC/HDL-C had
significant risk [adjusted HR1.31(1.10-1.57)].Among non-diabetic men, all lipid measures, except for TG, were
independent predictors for CVD however; a 1 SD increase in HDL-C significantly decreased the risk of CVD
[adjusted HR 0.83(0.70-0.97)].In non-diabetic women, TC, LDL-C, non-HDL-C and TG were independent predictors.
There was no difference in the discriminatory power of different lipid measures to predict incident CVD in the risk
factor adjusted models, in either sex of diabetic and non-diabetic population.
Conclusion: Our data according to important test performance characteristics provided evidence based support
for WHO recommendation that along with other CVD risk factors serum TC vs. LDL-C, non-HDL-C and TC/HDL-C is
a reasonable lipid measure to predict incident CVD among diabetic men. Importantly, HDL-C did not have a
protective effect for incident CVD among diabetic population; given that the HDL-C had a protective effect only
among non- diabetic men.
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Risk of cardiovascular disease (CVD) is 200% higher in
diabetic population than non-diabetic individuals [1] and
coronary heart disease (CHD) is the leading cause of
death among diabetic patients [2,3]. Furthermore, as
acknowledged by Haffner et al, type 2 diabetic patients
without prior myocardial infarction (MI) have as high a
risk of MI as non-diabetic patients with prior MI [4]. The
increased risk of CHD in diabetic patients is partly attri-
butable to higher prevalence of hypertension, obesity,
cigarette smoking and dyslipidemia [5]. It is well known
that type 2 diabetes is associated with high prevalence of
dyslipidemia, including elevated triglycerides (TG) and
reduced high-density lipoprotein cholesterol (HDL-C)
and increased low-density lipoprotein cholesterol (LDL-
C) particle with altered composition [6]. Diabetes is often
associated with many other atherogenic lipoprotein
abnormalities characterized by elevated very low density
lipoprotein (VLDL), intermediate density lipoprotein
(IDL) and chylomicron, and non-HDL-C, including all
apolipoprotein B containing atherogenic lipoproteins, has
been reported to be superior to LDL-C in predicting inci-
dent cardiovascular disease (CVD) in diabetic patients
[7,8]. However, total cholesterol (TC)/HDL-C was the
best predictor of CVD in diabetic males in the Health
Professionals’ Follow-up Study [8]. Hence, the relative
role of various lipid measures in determining CVD risk in
diabetic patients is still a subject of debate [9].
The Tehran Lipid and Glucose Study (TLGS) is a
population based study conducted on a representative
Iranian urban population, residents of the capital city,
Tehran [10]. This Iranian population has a high preva-
lence and incidence of type 2 diabetes, and Iranian men
and women with diabetes have more than 1.7 and 2.5
times risk of incident CVD respectively, independent of
traditional risk factors [11-13]. Furthermore, to our
knowledge, no previous study has directly compared the
predictive power of lipid measures in type 2 diabetic
patients among a Middle Eastern population, which has
the highest rate of type 2 diabetes predicted by 2030 [14].
Hence, considering the ethnical differences in CVD risk
factors and cultural/lifestyle practices, the aim of this
study is to evaluate the ability of different lipid measures
head-to head for predicting CVD risk in Iranian men and
women with and without type 2 diabetes using important
performance measures of prediction models including
model discrimination (evaluated by C index) [15], a sta-
tistic has rarely been applied in the similar studies.
Methods
Study population
Subjects in this study were drown among participants of
the TLGS, a prospective study to determine the risk
factors and outcomes for non-communicable disease.
TLGS has been performed on a representative sample of
15005 people aged 3 years and over, residents of dis-
trict-13 of Tehran; subjects were categorized into the
cohort and intervention groups, the latter to be edu-
cated for implementation of life style modifications
[10,16].
From this overall group, 7614 individuals (1358 dia-
betic and 6256 non-diabetic subjects) aged 30 years old
and over were evaluated in a cross-sectional phase of
TLGS (February 1999 to August 2001). Subjects with a
history of CVD at baseline (n = 518) were excluded,
leaving 7096 individuals; of whom 1021 diabetic (men =
413, women = 608) and 5310 non-diabetic subjects
(men = 2317, women = 2993) were followed up March
2009 with a median of 8.6 years (response rate 6331/
7096 ≈ 89%). The ethical committee of the Research
Institute for Endocrine Sciences approved this study and
informed written consent was obtained from all subjects.
Clinical and laboratory measurements
Using a pretested questionnaire, a trained interviewer
collected information which included demographic data,
past medical history and family history of CVD, con-
sumption of antihypertensive and lipid lowering drugs
and smoking behavior. Subjects were also questioned
about past history of diabetes mellitus and taking of any
anti-diabetic drugs. Weight was measured, while sub-
jects were minimally clothed without shoes, using digital
scales (Seca 707, Seca Corp., Hanover, MD; range 0.1-
150 kg) and recorded to the nearest 100 g. Height was
measured in a standing position without shoes, using
tape meter with shoulders in normal alignment. Body
mass index (BMI) was calculated as weight (kg) divided
by square of height (m
2). Waist circumference (WC)
was measured at umbilical level, using an unstretched
tape meter, without any pressure to body surface and
hip circumference (HC) at the maximal level over light
clothing. Waist to hip ratio (WHR) was calculated as
WC (cm) divided by HC (cm). Two measurements of
systolic and diastolic blood pressure (SBP and DBP,
respectively) were taken using a standardized mercury
sphygmomanometer (calibrated by the Iranian Institute
of Standards and Industrial Researches) on the right
arm, after a 15 minute rest in a sitting position; mean of
the two measurements was considered as subject’s blood
pressure. A blood sample was drawn between 7:00 and
9:00 AM from all study participants after 12-14 h over-
night fasting. All the blood analyses were done at the
TLGS research laboratory on the day of blood collec-
tion. Plasma glucose was measured using an enzymatic
colorimetric method with glucose oxidase. The standard
oral glucose tolorance test (OGTT) was performed for
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assayed using enzymatic colorimetric method with cho-
lesterol esterase and cholesterol oxidase. HDL-C was
measured after precipitation of the apolipoprotein B-
containing lipoproteins with phosphotungstic acid. TG
was assayed using an enzymatic colorimetric method
with glycerol phosphate oxidase. These analyses were
performed using commercial kits (Pars Azmoon Inc.,
Tehran, Iran) and a Selectra 2 auto analyzer (Vital
Scientific, Spankeren, The Netherlands). In subjects
whose TG concentration was below 4.52 mmol/L, LDL-
C was calculated from serum TC, TG and HDL-C con-
centration, using the Friedewald formula [17]. Non-
HDL-C was calculated by subtracting HDL-C from TC;
TC/HDL-C and TG/HDL-C were calculated by dividing
TC and TG to HDL-C respectively. The intra- and
inter-assay coefficients of variation (CV) were both 2.2%
for glucose. For both total and HDL-Cholestrol, intra-
and inter-assay CVs were 0.5 and 2% respectively. Intra-
and inter-assay CVs were 0.6 and 1.6% for TG respec-
tively [10,16].
CVD outcome
Details of the collection of cardiovascular outcome data
have been published elsewhere [18]. To summarize,
each participant was followed up for any medical event
annually by phone calls. They were asked for any medi-
cal condition by a trained nurse and then a trained phy-
sician collected complementary data regarding that
event during a home visit and by acquisition of data
from medical files. The collected data were then evalu-
ated by an outcome committee consisting of an inter-
nist, an endocrinologist, a cardiologist, an epidemiologist
and other experts, when needed, to assign a specific out-
come for every event. In this study, our desired events
were the first CVD events, including definite MI [with
diagnostic electrocardiogram (ECG) and biomarkers],
probable MI (positive ECG findings plus cardiac symp-
toms or signs plus missing biomarkers or positive ECG
findings plus equivocal biomarkers [19], unstable angina
(new cardiac symptoms or changing symptom patterns
and positive ECG findings with normal biomarkers),
angiographic proven CHD, stroke (as defined by a new
n e u r o l o g i c a ld e f i c i tt h a tl a s t e dm o r et h a n2 4h )a n d
death from CVD.
Definition of terms
Diabetes mellitus was defined as fasting plasma glucose
(FPG) ≥ 7 mmol/L, 2 hours plasma glucose ≥ 11.1
mmol/L, current use of anti-diabetic drugs [20] or a
positive answer to the question “have you ever been told
by a doctor that you have diabetes (high blood sugar
disease)?” A positive family history of premature CVD
reflected any prior diagnosis of CVD by a physician in
any female first-degree relative under 65 years old, and
a n ym a l ef i r s t - d e g r e er e l a t i v ea g e d5 5y e a r s .S m o k i n g
status included current regular or occasional use of
cigarettes. According to the World Health Organization
(WHO) definition, menopause was defined as absence
of spontaneous menstural bleeding for more than 12
months, for which no other pathologic or physiologic
cause could be determined [21].
Statistics
Mean (standard deviation: SD) values for continous and
frequencies (%) for categorical variables of the baseline
characteristics including lipid measures are expressed
for diabetic and non-diabetic participants, with and
w i t h o u tC V D .S i n c eF P G ,T G ,a n dT G / H D L - Ch a d
skewed distribution they are shown as median (inter-
quartile range). Comparison of baseline characteristics
between subjects with and without CVD was done by
student’s t-test for continuous variables, chi-square test
for categorical variables and Mann-Whitney test for
skewed variables.
Cox proportional hazard model was used to study the
association of lipid measures with CVD outcome. Follow
up duration was defined as the period between entrance
to study and the end points; end point was considered
as the first CVD event and censoring which was defined
as leaving the residence area, loss to follow up or non-
CVD death or March 2009. To select covariates to be
included in the multivariate Cox models, univariate ana-
lysis was used for each candidate covariate (age, family
history of premature CVD, intervention group, WHR,
SBP, DBP, FPG, smoking, aspirin use, antihypertensive
and lipid lowering drugs in both genders and meno-
pause status in women); following this, each covariate
that had a P value less than 0.2 in the univariate analy-
sis, was selected to be included in a stepwise backward
(P remove ≤ 0.1) multivariate Cox regression analysis. In
diabetic men, final covariat e sw e r ea g e ,F P G ,S B Pa n d
lipid lowering drugs; in diabetic women these were
WHR, FPG, SBP, lipid lowering drugs use, family history
of premature CVD and menopause status. Among non-
diabetic men, final covariates were age, family history of
premature CVD, WHR, SBP and aspirin; in non-diabetic
women those were age, WHR, DBP, smoking status,
antihypertensive drug use and positive family history of
premature CVD. Each final model included these covari-
ates plus one of the lipid measures. Adjusted hazard
ratios (HRs), with 95% confidence intervals (CI), were
calculated for every 1 SD increase in the value of each
lipid measures.TG and TG/HDL were log-transformed
and their HRs were calculated for 1 DS increase in log-
transformed TG and TG/HDL. The proportional
hazards assumption in the Cox model was assessed with
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assumptions were appropriate.
To determine the goodness of fit of the predictive
models, the Akaike Information Criterion (AIC), as a
statistical estimate of the trade-off between the likeli-
hood of a model against its complexity was used. A
lower value of AIC indicates a better model fit [22]. The
discrimination ability of the models was calculated using
the C index [15]. A value of 1 denotes perfect discrimi-
nation and a value of 0.5 is no better than chance. The
C indices of multivariate Cox models were compared
using the “somersd” STATA command which calculated
confidence interval for the Harrell’s C index using jack-
knife variance estimation [23]. The STATA software
(version 10) was used for data analysis and P-values ≤
0.05 were considered statistically significant.
Results
The study sample consisted of 1021 diabetic individuals
(men = 413, women = 608) and 5310 non-diabetic sub-
jects (men = 2317, women = 2993) with mean age of
54.8 and 45.8 year, respectively. Among the diabetic
population, of 1021 diabetic subjects 161 cases (15.7%)
were identified only by the positive response to the rele-
vant question at baseline. There was no significant dif-
ference between subjects followed and those non-
followed, in age, CVD risk factors and lipid markers or
indices. During a median follow up of 8.6 years, 189
(men = 91, women = 98) and 263(men = 169, women =
94) first CVD events occurred, in diabetic and non-dia-
betic population, respectively.
Baseline characteristics in diabetic and non-diabetic,
with and without CVD events, are summarized in table
1. In diabetic individuals, in comparison with subjects
without CVD, those with CVD were older and had sig-
nificantly higher WHR, SBP, DBP, FPG, TC, LDL-C,
TG, non-HDL-C, TC/HDL-C and TG/HDL and higher
rate of aspirin, lipid-lowering and antihypertensive drugs
consumption; similarly, non-diabetic subjects with CVD
w e r eo l d e ra n dh a dh i g h e rW H R ,S B P ,D B P ,F P Ga n d
all lipid parameters, but for HDL-C which had lower
values in those with CVD. Using aspirin, antihyperten-
sive and lipid lowering drugs were higher in non-dia-
betic subjects with CVD. Furthermore, the prevalence of
smoking and family history of premature CVD was sig-
nificantly higher in non-diabetic individuals with CVD.
Table 2 and table 3 present HRs of a 1 SD increase in
each lipid marker or index for first CVD event, in diabetic
and non-diabetic men and women, respectively. In dia-
betic men, in age adjusted Cox proportional hazard mod-
els, there was positive association between TC, LDL-C,
non-HDL-C, TG, TC/HDL-C, and TG/HDL-C with CVD
events. After further adjustment for SBP, FPG and lipid-
lowering drugs, the associations of these lipids with CVD
attenuated, but were still significant for TC, LDL-C, non-
HDL-C, TC/HDL-C. Furthermore, a 1 SD increase in log-
Table 1 General Characteristics of diabetic and non-diabetic subjects with and without cardiovascular disease
With diabetes Without diabetes
without CVD (n = 832) with CVD (n = 189) P Value without CVD (n = 5047) with CVD (n = 263) P Value
Age 53.9 ± 11.2 58.5 ± 9.6 <0.001 45.2 ± 11.7 56.9 ± 10.7 <0.001
FH premature CVD (%) 18.6 23.8 0.10 15.6 21.4 0.01
Cigarette smoking (%) 10.2 12.7 0.32 14.7 23.7 <0.001
Aspirin use (%) 16.7 24.7 0.01 10.6 20.2 <0.001
Lipid-lowering drug use (%) 8.4 17.0 <0.001 2.5 4.9 0.01
Antihypertensive drug use
(%)
16.4 29.1 <0.001 5.5 20.2 <0.001
BMI (kg/m2) 28.8 ± 4.9 28.9 ± 4.1 0.70 27.1 ± 4.5 27.7 ± 4.6 0.03
WHR 0.93 ± 0.08 0.96 ± 0.07 <0.001 0.87 ± 0.08 0.93 ± 0.07 <0.001
SBP (mmHg) 131.4 ± 21 143.4 ± 25 <0.001 118.9 ± 17.8 133.9 ± 22.8 <0.001
DBP (mmHg) 82.0 ± 10 85.6 ± 14 0.001 78.2 ± 10.4 83.3 ± 13.3 <0.001
FPG (mmol/L) 7.2(5.8-9.6) 8.5(6.9-11.8) <0.001 4.9(4.6-5.3) 5.1(4.7-5.4) 0.002
TC (mmol/L) 5.9 ± 1.2 6.4 ± 1.3 <0.001 5.5 ± 1.1 5.9 ± 1.2 <0.001
LDL-C (mmol/L) 3.7 ± 0.99 4.1 ± 1.11 <0.001 3.5 ± 0.95 3.9 ± 1.05 <0.001
HDL-C (mmol/L) 1.07 ± 0.28 1.03 ± 0.27 0.07 1.09 ± 0.28 1.05 ± 0.27 0.03
TG (mmol/L) 2.2(1.6-3.2) 2.5(1.8-3.4) 0.005 1.7(1.1-2.4) 1.8(1.4-2.7) <0.001
Non-HDL-C (mmol/L) 5.0 ± 1.2 5.3 ± 1.3 <0.001 4.4 ± 1.1 5.0 ± 1.1 <0.001
TG/HDL-C 2.1(1.4-3.3) 2.3(1.7-3.8) 0.006 1.5(0.9-2.4) 1.8(1.2-2.9) <0.001
TC/HDL-C 5.8 ± 1.9 6.6 ± 2.2 <0.001 5.3 ± 1.6 5.9 ± 1.7 <0.001
Mean ± SD are shown for continuous variables and P value is calculated with t-test; % is shown for categorical variables with P value according to chi-square; TG,
TG/HDL and FPG are shown as median (interquartile range) and P value according to Mann-whitney test. CVD: Cardiovascular disease, FH: family history, BMI:
body mass index, WHR: waist to hip ratio, SBP: systolic blood pressure, DBP: diastolic blood pressure, FPG: fasting plasma glucose, TC: total cholesterol, LDL-C:
Low-density Lipoprotein, HDL-C: High density lipoprotein, TG: triglyceride.
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23%, p = 0.06). In men, a 1 SD increase of lipid measures
increased risk of CVD events from 16% to 45% in the full
adjusted models, depending on the lipid measures. In dia-
betic women, a 1 SD increase of TC, LDL-C, non-HDL-C,
TG, TC/HDL-C and TG/HDL-C resulted in a significant
risk of incident CVD in age adjusted model, however; a 1
SD increase in HDL-C decreased the risk of CVD ≈ 19%
[0.81(0.65-1.01), P = 0.06]. Considering multivariate analy-
sis, only TC/HDL-C was significantly associated with CVD
event [1.31(1.10-1.57), P = 0.002], albeit a 1 SD increase in
LDL-C and non-HDL-C resulted in an 18% increased risk
of CVD. The non significant association of LDL-C and
non-HDL-C in diabetic women with incident CVD might
be partly attributed to the limited statistical power. With
our sample size and a of 0.05, we had the statistical power
to detect an HR of 1.20 and 1.30 per 1 SD increment of
30% and 74% respectively, in diabetic women with incident
CVD.
Among non-diabetic men, in age adjusted models, all
lipid measures were significantly associated with risk of
CVD. After further adjustment for risk factors, all of the
lipid measures remained significant predictors of CVD
except for TG. The multivariate HRs of a 1 SD increase
in TC, LDL-C, non-HDL-C, TC/HDL-C and TG/HDL-
C for predicting CVD were 1.21, 1.23, 1.27, 1.29 and
1 . 2 0r e s p e c t i v e l y .A1S Di n c r e a s eo fH D L - Cd e c r e a s e d
risk of CVD by 17% in both models in non-diabetic
men. In women without diabetes, a 1 SD increase of
TC, LDL-C, non-HDL-C, TG, TC/HDL-C and TG/
HDL-C were associated with 24% to 36% increased risk
of CVD (all P value < 0.05) depending on lipid markers,
in age adjusted models. However, after further adjust-
ment for risk factors, TC, LDL-C, non-HDL-C and TG
were significantly associated with incident CVD. In non-
diabetic women, HDL-C did not show any association
with CVD risk in both models.
Regarding the discriminatory power of the models, we
found that multivariate models with different lipid mea-
sures had relatively the same C index in each of the
genders in both diabetic and non-diabetic (P > 0.05 for
differences in C indices).
According to AIC, LDL-C had the best fitness in multi-
variate models in diabetic men, followed by non-HDL-C,
TC/HDL-C and TC. In women with diabetes, the LDL-C
highlighted the best fitted multivariate model, followed
by TC/HDL-C. Similarly in non-diabetic men, the smal-
lest AIC in the multivariate models belonged to the LDL-
C model followed by TC/HDL-C. In non-diabetic
women, according to AIC, the LDL-C model was the fit-
test model, however, the TC, non-HDL-C, TG models
showed similar AICs, which were more than LDL-C.
Table 2 Hazard ratios and discrimination of lipid measures for predicting cardiovascular events in diabetic men and
women
Age adjusted model Multivariate adjusted model
SD (mmol/L) Hazard ratio (95%CI) P value Hazard ratio (95%CI) P value C index (95% CI) AIC
men
TC 1.18 1.46(1.21-1.75) <.001 1.39(1.15-1.70) 0.001 0.70(0.65-0.75) 994
LDL-C 0.96 1.47(1.18-1.83) <.001 1.45(1.16-1.83) 0.001 0.70(0.65-0.76) 804
HDL-C 0.26 0.90(0.71-1.12) 0.36 0.91(0.72-1.16) 0.47 0.68(0.62-0.73) 989
Non-HDL-C 1.16 1.45(1.20-1.74) <.001 1.36(1.14-1.63) 0.001 0.70(0.65-0.75) 980
TG 0.58* 1.27(1.03-1.57) 0.02 1.23(0.99-1.53) 0.06 0.68(0.63-0.74) 1001
TC/HDL-C 2.20 1.18(1.04-1.34) 0.008 1.16(1.01-1.33) 0.02 0.69(0.64-0.74) 986
TG/HDL-C 0.71* 1.22(0.99-1.49) 0.05 1.18(0.96-1.47) 0.11 0.68(0.62-0.73) 987
women
TC 1.29 1.32(1.11-1.57) 0.001 1.13(0.93-1.37) 0.19 0.73(0.68-0.77) 1137
LDL-C 1.04 1.33(1.11-1.59) 0.002 1.18(0.97-1.44) 0.09 0.73 (0.68-0.78) 980
HDL-C 0.28 0.81(0.65-1.01) 0.06 0.82(0.66-1.02) 0.08 0.73(0.68-0.77) 1126
Non-HDL-C 1.28 1.37(1.16-1.62) <.001 1.18(0.98-1.42) 0.07 0.73(0.69-0.78) 1126
TG 0.51* 1.22(1.01-1.48) 0.03 1.08(0.89-1.33) 0.4 0.72(0.67-0.77) 1138
TC/HDL-C 1.80 1.44(1.24-1.68) <.001 1.31(1.10-1.57) 0.002 0.74(0.70-0.79) 1121
TG/HDL-C 0.62* 1.30(1.07-1.59) 0.007 1.16(0.95-1.42) 0.12 0.72(0.69-0.78) 1127
SD: standard deviation.TC: total cholesterol, LDL-C: low density lipoprotein cholesterol, HDL-C: high density lipoprotein cholesterol, TG: triglyceride, CI: confidence
interval. Hazard ratios indicate the increase risk for a 1 SD increase of each lipid parameter. Multivariate models were adjusted for age, systolic blood pressure
(SBP), Fasting plasma glucose (FPG) and lipid lowering drug use in men and were adjusted for SBP, FPG, waist to hip ratio, lipid lowering drug use, menopause
status and family history of premature cardiovascular disease in women. AIC (Akaike Information Criterion) is a statistical estimate of the trade-off between the
likelihood of a model against its complexity; a lower value of AIC indicates a better model fit. The discrimination ability of the models was calculated using the C
index. A value of 1 denotes perfect discrimination and a value of 0.5 is no better than chance. *SD of log-transformed.
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LDL-C, non-HDL-C and TC/HDL-C for incident CVD
in diabetic participants with TG levels ≥ 2.26 and <2.26
mmol/L in sex pooled analysis. The associations of the
lipid measures with CVD risk were stronger among dia-
betic participants with lower TG levels than those with
higher TG levels (Table 4). However, tests for interac-
tion of TG with mentioned lipids were all non signifi-
cant (all P value > 0.05).
Discussion
In this population based prospective cohort of diabetic
and non-diabetic Iranian men and women, we examined
different lipid measures as predictors of CVD events
using multivariable Cox regression analysis. In diabetic
men, TC, LDL-C, non-HDL-C, and TC/HDL-C
remained as independent predictors of incident CVD.
Although the differences were small in discriminatory
terms (as assessed by C index), the LDL-C model had
the better fitted model (as assessed by AIC) followed by
the non-HDL-C, TC/HDL-C, TC and TG models. In
diabetic women, after adjustment for CVD risk factors,
only TC/HDL-C resulted in a significant risk for CVD.
Similarly in diabetic women, although the differences
were small in discriminatory terms, LDL-C had the bet-
ter fitted model followed by TC/HDL-C model. Among
non-diabetic men, all lipid measures, except for TG,
were independent predictors for CVD; a 1 SD increase
in HDL-C however, significantly decreased the risk of
CVD, with almost same discriminatory power. In female
non-diabetic population, TC, LDL-C, non-HDL-C and
TG showed significant association with CVD event with
the same discrimination in full adjusted analysis.
Table 3 Hazard ratios and discrimination of lipid measures for predicting cardiovascular events in non-diabetic men
and women
Age adjusted model Multivariate adjusted model
SD (mmol/L) Hazard ratio (95%CI) P value Hazard ratio (95%CI) P value C index (95% CI) AIC
men
TC 1.07 1.25(1.08-1.44) 0.002 1.21(1.04-1.41) 0.009 0.76(0.73-0.80) 2389
LDL-C 0.91 1.24(1.07-1.44) 0.004 1.23(1.06-1.44) 0.006 0.77(0.74-0.80) 2236
HDL-C 0.24 0.83(0.71-0.97) 0.026 0.83(0.70-0.97) 0.02 0.77(0.73-0.80) 2374
Non-HDL-C 1.07 1.30(1.13-1.50) <0.001 1.27(1.10-1.48) 0.001 0.77(0.74-0.80) 2369
TG 0.54* 1.19(1.03-1.37) 0.013 1.13(0.96-1.32) 0.12 0.76(0.73-0.79) 2393
TC/HDL-C 1.71 1.28(1.12-1.46) <0.001 1.29(1.12-1.48) <0.001 0.77(0.74-0.80) 2368
TG/HDL-C 0.68* 1.25(1.07-1.47) 0.005 1.20(1.01-1.43) 0.03 0.76(0.73-0.80) 2375
women
TC 1.17 1.29(1.08-1.55) 0.005 1.22(1.01-1.48) 0.03 0.84(0.81-0.87) 1313
LDL-C 0.98 1.30(1.06-1.59) 0.01 1.22(0.99-1.49) 0.05 0.84(0.80-0.87) 1206
HDL-C 0.28 0.95(0.78-1.17) 0.68 1.00(0.81-1.24) 0.94 0.84(0.80-0.87) 1317
Non-HDL-C 1.18 1.30(1.08-1.56) 0.004 1.22(1.01-1.48) 0.03 0.84(0.81-0.87) 1313
TG 0.52* 1.36(1.10-1.68) 0.004 1.27(1.01-1.59) 0.03 0.84(0.81-0.87) 1313
TC/HDL-C 1.63 1.24(1.04-1.47) 0.01 1.17(0.97-1.41) 0.09 0.84(0.81-0.87) 1314
TG/HDL-C 0.66* 1.30(1.05-1.62) 0.01 1.21(0.96-1.52) 0.10 0.84(0.80-0.87) 1314
SD: standard deviation, TC: total cholesterol, LDL-C: low density lipoprotein cholesterol, HDL-C: high density lipoprotein cholesterol, TG: triglyceride, CI: confidence
interval. Hazard ratios indicate the increase risk for a 1 SD increase of each lipid parameter. Multivariate models were adjusted for age, family history of premature CVD,
WHR, SBP and aspirin in men and were adjusted for age, WHR, DBP, smoking status, antihypertensive drug use and family history of premature CVD age, WHR, DBP,
smoking status, antihypertensive drug use and positive family history of premature CVD in women. AIC (Akaike Information Criterion) is a statisticale s t i m a t eo ft h e
trade-off between the likelihood of a model against its complexity; a lower value of AIC indicates a better model fit. The discrimination ability of them o d e l sw a s
calculated using the C index. A value of 1 denotes perfect discrimination and a value of 0.5 is no better than chance. *SD of log-transformed.
Table 4 Adjusted Hazard ratios for cardiovascular disease
in diabetic subjects with Triglyceride level less and more
than 2.26 mmol/L
Triglyceride ≥ 2.26 mmol/L Triglyceride < 2.26
mmol/L
Hazard ratio (95% CI) P
value
Hazard ratio
(95% CI)
P
value
TC 1.23(1.03-1.45) 0.01 1.40(1.04-1.89) 0.02
LDL-C 1.30(1.07-1.57) 0.007 1.39(1.07-1.81) 0.01
Non-
HDL-C
1.24(1.04-1.47) 0.01 1.46(1.09-1.97) 0.01
TC/HDL-
C
1.18(1.05-1.33) 0.004 1.74(1.19-2.55) 0.004
TC: total cholesterol, LDL: low density lipoprotein cholesterol, HDL-C: high
density lipoprotein cholesterol. Hazard ratios indicate the increase risk for a 1
standard deviation increase of each lipid measures; adjusted for age, sex,
systolic blood pressure, fasting plasma glucose, lipid lowering drug use, waist
to hip ratio and positive family history of premature cardiovascular disease.
The method of selection of the covariates is mentioned in statistics.
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Page 6 of 9A large body of evidence has shown that high serum
TC and LDL-C are risk factors for CVD in the diabetic
and non-diabetic population [24,25]. The current study
yielded the same discriminatory power for TC and LDL-
C in both genders of diabetic and non-diabetic popula-
tion, although based on the AIC; the LDL-C model had
better risk prediction. In the Asia Pacific Cohort Studies
Collaboration for each increase of a 1 SD in TC, partici-
pants with diabetes had a 41% (95%CI: 23-63%) greater
risk of CHD in age and sex adjusted analysis [26]; the
corresponding estimate for male participants in our
study was 39% (15%-70%). Indeed, the predictive power
of the Framingham coronary risk score does not change
when LDL-C is used in place of TC [27]. When plasma
TG levels are not so high, the plasma TC is generally
correspondent with LDL-C level; therefore, in a diabetic
population with a high prevalence of hypertriglyceride-
mia (in our study 10.7% of the whole diabetic popula-
tion have TG ≥ 4.52 mmol/L) the use of LDL-C might
be better than that of TC [28].
Previous studies have reported the role of non-HDL-C
in prediction of CVD risk among diabetic and non-dia-
betic population, as a simple and reproducible lipid
measure which does not need fasting state for its mea-
surement [7,8,29,30]. Our finding demonstrated that
among the non-diabetic population, non-HDL-C was a
significant predictor of incident CVD in both genders;
similar to the association shown among non-diabetic
Arab community [30]. In diabetic population strong evi-
dence for its superiority over TC, LDL-C (as the main
lipid target) and TC/HDL-C is not yet available [31]. In
diabetic men of the Health Professionals’ Follow-up
Study, comparisons of nested models highlighted that
non-HDL-C, but not ApoB, add significantly to the pre-
diction of CVD risk beyond LDL-C; nevertheless, in this
study TC/HDL-C was the best predictor of CVD [8].
Furthermore in the Strong Heart Study, the HRs for the
highest tertile of non-HDL-C in men and women with
diabetes were higher than those for either LDL-C or TG
per se in both genders and were higher than the TC/
HDL-C in women, although the CIs overlapped [7]. In
our data analysis, TC/HDL-C and non-HDL-C had
same discriminatory power and relatively the same
model fitness in both genders of diabetic population;
although non-HDL-C in men and TC/HDL-C in women
had the least AIC (except LDL-C). Hence, the similarity
of the C index between TC/HDL-C and non-HDL-C to
predict incident CVD in our study indicates that, at
least in type 2 diabetic patients the difference is not
clinically important as reported by Holman et al in the
U.K. Prospective Diabetes Study (UKPDS) [32]. In agree-
ment with the findings of our study, non-HDL-C was
associated with CVD risk among diabetic subjects inde-
pendent of their TG levels as shown in other diabetic
cohorts [7,8]. However, in contrast to the Strong Heart
Study, the significant risk of TC/HDL-C in prediction of
incident CVD was not affected by TG levels [7].
In this study, among the diabetic population, HDL-C
in both genders was not associated with incident CVD,
although there was significant protective effect of HDL-
C in non-diabetic men. Oant et al. showed that in the
general Turkish adult population, a 12 mg/dl increase of
HDL-C in men, decreased the risk of CHD by 20%,
whereas HDL-C did not protect the development of
CHD in women [33]; similarly ≈ 9 mg/dl (0.24 mmol/L)
increase in HDL-C decreased by the 17% risk of CVD in
our non-diabetic men, but not in non-diabetic women.
Our data analyses support the issue that the atheropro-
tective effect of HDL-C may be deficient in subjects
with type 2 diabetes mellitus [33]. As acknowledged by
Kuntush et al, the compositional modification of the
HDL-C lipid core and conformational change of ApoA-
1 might lead to functional alteration of the HDL-C par-
ticle in type 2 diabetes[34]. In our results, TG was not
associated with CVD in diabetic females and has a mar-
ginal association in diabetic males. In line with current
results, HDL-C and TG were not associated with inci-
dent CHD in diabetic women of Nurses’ Health Study
during 10 years of follow-up [29]. Schulze et al sug-
gested that the risk of TG and protective effect of HDL-
C were present only among women with low HbA1C
and this association was not present among those with
poorly controlled diabetes [29]. Furthermore, in diabetic
adult men of the Health Professionals’ Follow-up Study
and the Strong Heart Study the serum TG was an inde-
pendent predictor of CVD risk [7,8].
In the current study, TG/HDL-C did not show any
association with CVD in both genders of diabetic popu-
lation and also in non-diabetic women. However, as
recently showed in general men population, TG/HDL-C
remained as an independent predictor of incident CVD
among non-diabetic men population [35].
There are several points that should be considered
when considering the results of this study. First, we
measured TC, HDL-C and TG only once at the baseline
per subject, thus the potential bias resulting from
regression dilution of TG and HDL-C could not be
ignored [36]; additionally, given the significant intra-
individual variation in fasting TG level, it might be pos-
sible that a proportion of participants who had a high
concentration of TG are falsely classified as low, and
vice versa; hence, attenuating the true relative risk of
the lipoprotein. Second, ApoA-1 and ApoB were not
measured at the baseline; however, Ingelsson et al in a
large population based study highlighted that the overall
performance of ApoB/ApoA-1 for prediction of CHD
was comparable with that of traditional lipid ratios, and
did not result in incremental utility over TC/HDL-C
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Page 7 of 9[37]. Third, we did not consider the inflammatory para-
meters including CRP, fibrinogen and Apo A-1. Onat et
al recently showed that in a Turkish population with
high prevalence of metabolic syndrome, obesity and
hypertriglyceridemia and low HDL-C (a background
similar to residents of Tehran [38]) the positive correla-
tion observed between HDL-C and fibrinogen and Apo
A-1 might be cited as biological evidence of functional
impairment of HDL-C [33]. Fourth, we did not have
data regarding the level of glycemic control (i.e.
HbA1C) and duration of diabetes; the potent predictors
of CVD risk in diabetic patients [39], and hence, the
mentioned factors were not controlled in data analysis.
Additionally, we had no information regarding type of
diabetes, although by including persons aged ≥ 30 years,
we distinguished subjects with higher probability of type
2 than type 1 diabetes. Finally, some misclassification of
diabetes status may have occurred due to defining new
diagnosed diabetes with a single OGTT at baseline and
ap a r t i a lr e l i a n c eo ns e l f - r e ported history of diabetes.
However, the extent of misclassification would have to
be extensive to change the results of this study [26].
The strengths of our study include, the population
based sample consisting of diabetic men and women,
the continuous monitoring for CVD events and compre-
hensive assessment of several lipid measures using
model discrimination and fitness. As pointed by Ingels-
son et al, in studies focusing on prediction of incident
CVD, an analysis of the comparative performances in
terms of discrimination (C index) may be more impor-
tant than a comparison of relative risk estimates for
lipid measures [37]. Furthermore, given the relatively
equal performances of different lipid measures, other
factors including the costs, availability of assays and
educational needs for health care professional, the possi-
bility of obtaining accurate lipid measure in nonfasting
state (i.e. TC, TC/HDL-C and non-HDL-C) and the
availability of appropriate therapeutic cutoff points
should be borne in mind, when considering guiding the
choice of lipid measure that should be used in CVD risk
prediction [37].WHO recommended TC as the only
lipid parameter for CVD risk assessment of individuals
detected to have hypertension, diabetes or smoking
behavior in low and medium resource settings where it
is both time-consuming and costly to measure TC, TG,
LDL-C and HDL-C altogether [40].
Conclusions
Our data according to important test performance char-
acteristic provided evidence based support for WHO
recommendation that along with other CVD risk factors
serum TC vs. LDL-C, non-HDL-C and TC/HDL-C is a
reasonable lipid measure to predict incident CVD
among diabetic men of a Middle Eastern cohort.
Importantly, HDL-C did not have a protective effect for
incident CVD among diabetic population; given that the
HDL-C had a protective effect only among non-diabetic
men.
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